NDC 0378-0197-05
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0378-0197
- Requested NDC
- 0378-0197-05
- Package NDCs from labels
- 0378-0197-05
- Manufacturer
- National Council for Prescription Drug Programs
- Effective date
- 2013-02-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2013-02-13 | Indexing - Billing Unit |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0378-0197-01 | EA - Each | 0378-0197 | 705c1658-2999-4e88-b00b-270645844035 | 1 | 2012-07-24 |
| 0378-0197-05 | EA - Each | 0378-0197 | 4ae28794-a74e-4ae7-bbf0-2fa45be72791 | 1 | 2013-02-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Diclofenac sodium and Misoprostol | DICLOFENAC SODIUM AND MISOPROSTOL | Mylan Pharmaceuticals Inc. | a7701e8c-4e16-4165-8b83-de2c08d5ded3 | 2026-08-31 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Sumatriptan Succinate | SUMATRIPTAN SUCCINATE | Mylan Pharmaceuticals Inc. | 1d2cd01c-05e7-44cf-a71d-0f474e826b7e | 2026-08-26 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Sulfasalazine | SULFASALAZINE | Mylan Pharmaceuticals Inc. | 257cee60-b68f-4c2b-b57d-8e4d73d17e09 | 2026-08-25 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| misoprostol | MISOPROSTOL | Mylan Pharmaceuticals Inc. | c4fe14fb-0a43-4c31-9cd6-29eb0d156705 | 2026-08-25 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Sulfasalazine | SULFASALAZINE | Mylan Pharmaceuticals Inc. | 48fbc535-a33a-45ee-85ff-9d1ec9b31d9c | 2026-08-25 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Saxagliptin and Metformin | SAXAGLIPTIN AND METFORMIN | Mylan Pharmaceuticals Inc. | cbf8677c-cafe-48bc-8844-0cc6547886bd | 2026-08-21 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Amnesteem | ISOTRETINOIN | Mylan Pharmaceuticals Inc. | b2cb63c9-f825-4991-9a2c-6260f1bbcc2c | 2026-08-15 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| clindamycin phosphate | CLINDAMYCIN PHOSPHATE | Mylan Pharmaceuticals Inc. | b52bdaf7-3b54-4165-9ab0-9dfa08170e47 | 2026-08-06 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Ethosuximide | ETHOSUXIMIDE | Mylan Pharmaceuticals Inc. | 19c924c2-f558-4c78-9277-2d7e0df2f505 | 2026-07-24 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Rifabutin | RIFABUTIN | Mylan Pharmaceuticals Inc. | c2026b67-4755-4236-96b6-a6b5e7399707 | 2026-07-20 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Nevirapine | NEVIRAPINE | Mylan Pharmaceuticals Inc. | c6e93829-7024-48f6-8023-da6ff27dfc0a | 2026-07-15 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Cimetidine | CIMETIDINE | Mylan Pharmaceuticals Inc. | 06c0a509-026f-44e0-9975-a94a8de51d43 | 2026-07-15 | Adverse reactions | Mylan Pharmaceuticals Inc. |
| Imatinib Mesylate | IMATINIB | Mylan Pharmaceuticals Inc. | a1787fad-3612-43e1-98fa-ce62361e0b3c | 2026-07-15 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Triazolam | TRIAZOLAM | Mylan Pharmaceuticals Inc. | 5add318e-11b9-42f8-b052-0d8cebb32fcf | 2026-07-10 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Linezolid | LINEZOLID | Mylan Pharmaceuticals Inc. | 83a84897-ccca-42a1-ab1a-bbf1d43a982b | 2026-07-09 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Cabergoline | CABERGOLINE | Mylan Pharmaceuticals Inc. | e497366b-a124-4d7f-bd45-a883c392d4bb | 2026-06-30 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Clonidine | CLONIDINE | Mylan Pharmaceuticals Inc. | 7adfc439-e6d0-4593-87dd-0eef36d33c6d | 2026-06-23 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Methylprednisolone | METHYLPREDNISOLONE | Mylan Pharmaceuticals Inc. | 22dd75d6-f89a-44f7-8ca6-b64c4e9806dd | 2026-06-22 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Atorvastatin Calcium | ATORVASTATIN CALCIUM | Mylan Pharmaceuticals Inc. | d0a0feb6-84f0-4693-a11f-eb4f7ae0a87d | 2026-06-15 | Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
| Metformin Hydrochloride | METFORMIN | Mylan Pharmaceuticals Inc. | 7e41818c-60e9-4bcf-9586-7bb8d33d5e89 | 2026-06-15 | Boxed warning, Warnings, Adverse reactions | Mylan Pharmaceuticals Inc. |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.